AFP and hepatocellular carcinoma: There are, however, no widely recognized blood or tissue biomarkers for predicting HCC response to ICB therapies in clinical use, and studies on serum biomarkers, such as alpha-fetoprotein (AFP), have returned inconsistent results (7–9).